Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis.

BACKGROUND: The development of an efficacious vaccine against infection with Helicobacter pylori, the causative agent of chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma, remains a challenge. Since the use of mucosal adjuvants is limited in human application, we have evaluated the...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Infectious Diseases Vol. 192; no. 8; pp. 1441 - 1450
Autores principales: Corthésy B, Boris S, Isler P, Grangette C, Mercenier A
Formato: pictorial research tables/charts Journal Article
Publicado: Oxford University Press / USA 10/15/2005
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106342805&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106342805
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00221899
        1YU
      jtl: Journal of Infectious Diseases
      issn: 00221899
      maglogo: N
    pubinfo:
      dt: 10/15/2005
      vid: 192
      iid: 8
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        106342805
        106342805
        2009283624
        10.1086/444425
        NLM16170763
        106342805
      ppf: 1441
      ppct: 9
      formats:
      tig:
        atl: Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis.
      aug:
        au:
          Corthésy B
          Boris S
          Isler P
          Grangette C
          Mercenier A
        affil: R&D Laboratory of the Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne Switzerland
      sug:
        subj:
          Bacterial Vaccines Administration and Dosage
          Helicobacter Infections Prevention and Control
          Helicobacter Pylori Drug Effects
          Administration, Oral
          Animal Studies
          Antibodies Blood
          Antibody Formation
          Antigens
          Bacterial Vaccines Immunology
          Bacterial Vaccines Pharmacodynamics
          Blotting, Western
          Cytokines
          Descriptive Statistics
          DNA Analysis
          Funding Source
          Helicobacter Infections Immunology
          Helicobacter Infections Physiopathology
          Immunoglobulins
          Immunoglobulins Blood
          Intestinal Mucosa Drug Effects
          Lactobacillus
          Mann-Whitney U Test
          Mice
          Models, Biological
          Polymerase Chain Reaction
          Recombinant Proteins Administration and Dosage
          Recombinant Proteins Immunology
          T-Tests
          Toxins
          Tumor Necrosis Factor
          Urease
      ab: BACKGROUND: The development of an efficacious vaccine against infection with Helicobacter pylori, the causative agent of chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma, remains a challenge. Since the use of mucosal adjuvants is limited in human application, we have evaluated the potential of recombinant Lactobacillus strains producing H. pylori urease B (UreB) subunit to deliver this antigen to the gastrointestinal tract. METHODS: Mice were injected orally 3 times with a triple dose of recombinant Lactobacillus plantarum NCIMB8826, the recombinant isogenic cell-wall mutant (alr(-) MD007 strain) expressing UreB, or a mixture of recombinant UreB and cholera toxin (rUreB/CT) as a control. Urease-specific seric immunoglobulin (Ig) G and IgA were measured by use of an enzyme-linked immunosorbent assay. After challenge with Helicobacter felis, stomach infection was examined by use of the rapid urease test and by polymerase chain reaction detection of Helicobacter genomic DNA. RESULTS: Intragastric immunization with both recombinant Lactobacillus strains and rUreB/CT elicited UreB-specific antibodies. After challenge, reduction of H. felis load in the stomachs of mice was observed only after immunization with the recombinant mutant strain MD007 or with rUreB/CT. CONCLUSIONS: This is the first report of successful induction of partial protection against H. felis with a mucosal prime-boost regimen in which recombinant Lactobacillus strains were used as antigen-delivery vehicles. Copyright © 2005 Infectious Diseases Society of America
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N